Events and news

Home > Blog > Toxicology

Environmental Risk Assessment. ERA reports

In accordance with Article 8(3) of Directive 2001/83/EC, an application for a marketing authorisation for a medicinal product for human use must be accompanied by an Environmental Risk Assessment (ERA). This assessment should be performed according to the European Medicines Agency, following the procedure described in Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (Doc. Ref. EMEA/CHMP/SWP/4447/00 corr. 21*) (1)

The environmental risk assessment process for a medicinal product is complex. It is based on overall usage, destination and transport, its persistence, and its ecotoxicity in the environment. The information available to assess this risk is often insufficient.

In the assessment of environmental risk two concepts have to be defined:

  • PEC (Predicted environmental concentration), which is the calculated concentration of a medicinal product in the environment. It depends on factors which increase or decrease the exposure of an organism to a substance (persistence, transport, destination and usage). According to EMA(1), for pharmaceuticals, PEC is calculated using a worst-case scenario, assuming no metabolism by the patient or removal/degradation of the substance and using the total sales volume in the corresponding country.

  • PNEC (Predicted no-effect concentration), which is the concentration, based on available tests, below which no adverse effects on the ecosystem are expected to occur for a specific organism. It is estimated using ecotoxicity testing data, by division of the lowest value for toxicity with the relevant assessment factor, as outlined by the EMA (1)

The environmental risk of a particular pharmaceutical can be quantified by the ratio PEC/PNEC. Depending on the PEC/PNEC ratio, the risk is divided into four different categories, consistent with the system for Environmental classification of pharmaceuticals at Swedish Prescribing guide (www.fass.se).

The risk categories are as follows:

Ratio Environmental risk level
PEC/PNEC ≤ 0.1 Insignificant
0.1 < PEC/PNEC ≤ 1 Low
1 < PEC/PNEC ≤ 10 Moderate
PEC/PNEC > 10 l High

At Azierta, science and health consulting, we have a specialized line in toxicological assessment being also corporate members of EUROTOX.

OUR SERVICES: We have accredited toxicologists and experts in the development of ERA REPORTS for any pharmaceutical product, always in accordance with the existing regulation. 

(1). Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (Doc. Ref. EMEA/CHMP/SWP/4447/00 corr. 21*)


Related posts

Polymeric materials in manufacturing processes: a new theat...

In the last few years, elastomer, thermoplastic or thermostable plastic polymeric materials have become established as basic...

Read more

Interview with Paulino Alonso: ICHQ3D on Elemental impurities...

ICHQ3D implementation involves a risk analysis to design strategies to control elemental impurities in drugs for human use,...

Read more

Líderes del sector farma & salud

100 professionals

Over 100 professionals

500 clients

Over 500 clients

9 year experience

9 years of experience


Leading innovation

Client oriented

100% client oriented

We are at your complete disposal for any inquiry

Schedule appointment

Schedule a video call with our field experts




Madrid (HQ)

Vía de las Dos Castillas 33, Edificio 7 - 28224 Pozuelo de Alarcón (Madrid)

912 77 10 76




Ctra. de l'Hospitalet, 147, Edificio Roma - 08940 Barcelona

912 77 10 76




Calle 25 nº 68-35

(+57) 3103498206




Avenida da Liberdade, 10

(+34) 91 277 10 76




Bastioni di Porta Nuova, 21 - 20121 Milan

(+34) 91 277 10 76




54 rue de Londres - 75008 Paris

(+33) 180 209 978


We use "cookies" to improve your experience on our site. Cookies enable us to tailor messages and display ads to your interests. They also help us understand how our site is being used. By continuing to use our site you consent to use our cookies.